Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc.
Regen BioPharma (OTCID:RGBP) was the subject of a new Goldman Small Cap Research report dated November 5, 2025 that highlights upcoming clinical and intellectual property milestones. The report notes Regen has an FDA-cleared IND for lead candidate HemaXellerate and plans a Phase I trial by year-end or early 1Q26.
Goldman emphasizes Regen's 11 issued patents and 17 pending, an ongoing Orphan Drug Designation application, and a peer-based valuation framework; the report includes a price target and argues shares are undervalued relative to Phase I peers.
Regen BioPharma (OTCID:RGBP) è stato oggetto di un nuovo rapporto di Goldman Small Cap Research datato 5 novembre 2025 che evidenzia imminenti traguardi clinici e di proprietà intellettuale. Il rapporto segnala che Regen dispone di un IND approvato dalla FDA per il candidato principale HemaXellerate e prevede un triale di Fase I entro la fine dell'anno o all'inizio del 1Q26.
Goldman enfatizza 11 brevetti emessi e 17 in attesa, una richiesta in corso per la Designazione di Farmaco Orfano e un quadro di valutazione basato sui peer; il rapporto include un obiettivo di prezzo e sostiene che le azioni siano sottovalutate rispetto ai peer di Fase I.
Regen BioPharma (OTCID:RGBP) fue objeto de un nuevo informe de Goldman Small Cap Research con fecha 5 de noviembre de 2025 que destaca próximos hitos clínicos y de propiedad intelectual. El informe señala que Regen cuenta con un IND aprobado por la FDA para su candidato principal HemaXellerate y prevé un ensayo de Fase I para finales de año o principios del 1T26.
Goldman enfatiza 11 patentes emitidas y 17 pendientes, una solicitud en curso de Designación de Droga Huérfana y un marco de valoración entre pares; el informe incluye un precio objetivo y argumenta que las acciones están subvaloradas en relación con pares de Fase I.
Regen BioPharma (OTCID:RGBP)는 2025년 11월 5일자로 된 Goldman Small Cap Research의 새로운 보고서의 대상이었으며, 향후 임상 및 지적 재산권 이정표를 강조합니다. 보고서는 Regen이 FDA 승인을 받은 IND를 보유하고 있으며 주요 후보군 HemaXellerate에 대해 연내 또는 1Q26 초기에 1상(Phase I) 시험을 계획하고 있다고 언급합니다.
Goldman은 Regen의 발급된 특허 11건 및 보류 중인 특허 17건, 그리고 오픈 Drug Designation(고아약 지정) 신청의 진행 상황, 동료 평가 기반의 평가 프레임워크를 강조합니다; 보고서는 목표 주가를 포함하고 주식이 1상 동료들에 비해 과소평가되어 있다고 주장합니다.
Regen BioPharma (OTCID:RGBP) a fait l’objet d’un nouveau rapport de Goldman Small Cap Research daté du 5 novembre 2025 qui met en évidence les prochaines étapes cliniques et les jalons de propriété intellectuelle. Le rapport indique que Regen dispose d’un IND approuvé par la FDA pour le candidat principal HemaXellerate et prévoit un essai de Phase I d’ici la fin de l’année ou au début du 1er trimestre 2026.
Goldman insiste sur 11 brevets délivrés et 17 en cours, une demande en cours de Désignation de Médicament Orphelin et un cadre d’évaluation par les pairs; le rapport inclut un objectif de cours et soutient que les actions sont sous-évaluées par rapport à leurs pairs de Phase I.
Regen BioPharma (OTCID:RGBP) war Gegenstand eines neuen Goldman Small Cap Research-Berichts vom 5. November 2025, der kommende klinische und intellektuelle Eigentumsmeilensteine hervorhebt. Der Bericht weist darauf hin, dass Regen über ein FDA-freigegebenes IND für den führenden Kandidaten HemaXellerate verfügt und einen Phase-I-Studie bis Ende des Jahres oder Anfang 1Q26 plant.
Goldman betont 11 erteilte Patente und 17 anhängige, eine laufende Orphan-Drug-Designation-Anmeldung und einen auf Peer-Vergleich basierenden Bewertungsrahmen; der Bericht enthält ein Kursziel und argumentiert, dass die Aktien im Vergleich zu Phase-I-Peers unterbewertet seien.
Regen BioPharma (OTCID:RGBP) كان موضوع تقرير جديد من Goldman Small Cap Research مؤرّخ في 5 نوفمبر 2025 يسلط الضوء على المعالم السريرية القادمة وحقوق الملكية الفكرية. يذكر التقرير أن Regen لديها IND معتمد من FDA للمُرشّح الرائد HemaXellerate ويخطّط لـ تجربة المرحلة الأولى بنهاية العام أو في بداية 1Q26.
Goldman يؤكد أن Regen لديها 11 براءة اختراع صادرة و17 قيد الانتظار، وتقديم طلب لتصنيف دواء يتيم جاري، وإطار تقييم قائم على أقران؛ يتضمن التقرير هدف سعر ويُ argue أن الأسهم مقومة بأقل من قيمتها مقارنةً بنظرائها في المرحلة I.
- FDA-cleared IND for HemaXellerate
- Planned Phase I launch by year-end or early 1Q26
- 11 patents awarded and 17 patents pending
- Orphan Drug Designation application in progress (potential pricing benefits)
- Phase I start timing uncertain: planned by year-end or early 1Q26
- Orphan Drug Designation is applied for but not yet granted
BALTIMORE, MD / ACCESS Newswire / November 5, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Regen BioPharma, Inc. (OTCID:RGBP, RGBPP), a biopharma developer that seeks to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. The Goldman report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download the report in its entirety, please visit: https://goldmansmallcapresearch.com/opportunity-research/imminent-phase-i-clinical-trial-launch-to-drive-major-valuation-upside/
Regen BioPharma, Inc. is focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology segment. The Company has an FDA-cleared IND for its Phase I clinical trial candidate HemaXellerate, an innovative stem cell-derived therapy.
In the Opportunity Research report, analyst Rob Goldman reviews this undervalued and underfollowed innovator including upcoming milestones and events, a peer group analysis, deep pipeline, and valuation drivers.
Set to Enter Clinical Stage
Goldman commented, "Regen is on the cusp of making a major leap from the preclinical biopharma stage to a clinical stage biopharma, which typically serves as a foundational valuation driver. The Company's lead candidate, HemaXellerate, is an innovative stem cell-derived therapy and the Company plans to launch a Phase I clinical trial by year-end or in early 1Q26. HemaXellerate's primary indication is to treat chemotherapy patients who have developed a potentially terminal side effect, severe aplastic anemia. The only approved therapy is a costly stem cell transplant, which needs a matched donor and can lead to graft-versus-host disease. Still, the Regen therapy represents
Multiple, Enviable Development Pathways
"Regen has applied for an Orphan Drug Designation for this product, which would be a major coup for the Company," noted Goldman. "There a number of advantages in receiving this award, including financial benefits. The median annual price tag for a drug with this designation, according to a NIH study, is
Imminent Phase I Launch to Raise Profile and Valuation
"We believe that these shares are undervalued based on the IP alone. When taking into account Regen's migration to the clinical stage, this status becomes even more pronounced, given the market cap assigned to its peers. Our price target reflects a meaningful discount to the Phase I clinical trial peer group," concluded Goldman.
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published company report on Regen BioPharma, Inc. ("The Company"). The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Regen BioPharma, Inc. The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our update about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download this research report, visit www.goldmansmallcapresearch.com. In 2023, Goldman Small Cap Research was compensated by a third party in the amount of
Goldman Small Cap Research
Rob Goldman, Analyst
410-800.7980
rob@goldmansmallcapresearch.com
SOURCE: Goldman Small Cap Research
View the original press release on ACCESS Newswire
FAQ
What did Goldman Small Cap Research announce about Regen BioPharma (RGBP) on November 5, 2025?
When does Regen BioPharma (RGBP) expect to start the HemaXellerate Phase I clinical trial?
Does Regen BioPharma (RGBP) have regulatory clearance to begin trials for HemaXellerate?
How strong is Regen BioPharma's (RGBP) intellectual property position?
What commercial advantages could Orphan Drug Designation provide Regen BioPharma (RGBP)?
What valuation view did Goldman express for Regen BioPharma (RGBP)?
